US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
AU763658B2
(en)
|
1998-06-02 |
2003-07-31 |
Osi Pharmaceuticals, Inc. |
Pyrrolo(2,3d)pyrimidine compositions and their use
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
GB9815567D0
(en)
*
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
AU6329599A
(en)
*
|
1998-09-28 |
2000-04-17 |
Glaxo Group Limited |
Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
|
GB9914821D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Glaxo Group Ltd |
Compounds
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
DK1370543T3
(da)
|
2001-02-14 |
2007-02-19 |
Tibotec Pharm Ltd |
Bredspektrede 2-(substitueret amino) benzothiazol- sulfonamid-HIV-proteaseinhibitorer
|
EE05384B1
(et)
|
2001-04-09 |
2011-02-15 |
Tibotec�Pharmaceuticals�Ltd. |
LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
|
AU2002310818B2
(en)
|
2001-05-11 |
2007-12-13 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
|
US7576084B2
(en)
*
|
2001-10-12 |
2009-08-18 |
Choongwae Pharma Corporation |
Reverse-turn mimetics and method relating thereto
|
EP2050751A1
(en)
|
2001-11-30 |
2009-04-22 |
OSI Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 and A3 receptors and uses thereof
|
AR037797A1
(es)
*
|
2001-12-12 |
2004-12-01 |
Tibotec Pharm Ltd |
Combinacion de inhibidores de proteasa dependientes del citocromo p450
|
CN1816551A
(zh)
|
2001-12-20 |
2006-08-09 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
|
KR20040068317A
(ko)
|
2001-12-20 |
2004-07-30 |
오에스아이 파마슈티컬스, 인코포레이티드 |
피리미딘 a₂b 선택성 길항 화합물, 그의 합성 방법 및용도
|
KR100942743B1
(ko)
|
2001-12-21 |
2010-02-16 |
티보텍 파마슈티칼즈 리미티드 |
광범위 스펙트럼 헤테로사이클릭 치환된 페닐 포함설폰아미드 hiv 프로테아제 저해제
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
US20060128692A1
(en)
|
2002-04-26 |
2006-06-15 |
Gilead Sciences, Inc |
Non nucleoside reverse transcriptase inhibitors
|
MXPA04011466A
(es)
|
2002-05-17 |
2005-02-14 |
Tibotec Pharm Ltd |
Inhibidores de la proteasa de hiv de benzisoxazol sulfonamida sustituida de amplio espectro.
|
EP1546153A1
(en)
|
2002-08-14 |
2005-06-29 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2425031A1
(en)
*
|
2003-04-01 |
2004-10-01 |
Smithkline Beecham Corporation |
Pharmaceutical compositions
|
US7417055B2
(en)
|
2003-04-25 |
2008-08-26 |
Gilead Sciences, Inc. |
Kinase inhibitory phosphonate analogs
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
WO2004096287A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7429565B2
(en)
|
2003-04-25 |
2008-09-30 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
EA200600221A1
(ru)
|
2003-07-09 |
2006-06-30 |
Пэрэтек Фамэсьютикэлс, Инк. |
Замещённые соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
|
EP2292590A3
(en)
*
|
2003-07-09 |
2012-05-02 |
Paratek Pharmaceuticals, Inc. |
Prodrugs of 9-aminomethyl tetracycline compounds
|
US20050119163A1
(en)
*
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
US7432273B2
(en)
|
2003-10-24 |
2008-10-07 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
US8193227B2
(en)
|
2003-12-11 |
2012-06-05 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US7834043B2
(en)
*
|
2003-12-11 |
2010-11-16 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US20050131042A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Flentge Charles A. |
HIV protease inhibiting compounds
|
PL1699455T3
(pl)
*
|
2003-12-15 |
2013-10-31 |
Merck Sharp & Dohme |
Heterocykliczne inhibitory proteaz aspartylowych
|
CA2549869C
(en)
|
2003-12-18 |
2015-05-05 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
|
WO2005063751A1
(en)
|
2003-12-22 |
2005-07-14 |
Gilead Sciences, Inc. |
4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
|
US7718633B2
(en)
|
2004-07-06 |
2010-05-18 |
Abbott Laboratories |
Prodrugs of HIV protease inhibitors
|
JP2008508291A
(ja)
|
2004-07-27 |
2008-03-21 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗hiv剤としてのヌクレオシドホスホネート結合体
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
EP2165709B1
(en)
*
|
2004-08-02 |
2016-03-16 |
Ambrilia Biopharma Inc. |
Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent
|
EP1789030A2
(en)
|
2004-08-30 |
2007-05-30 |
Interstitial Therapeutics |
Medical implant provided with inhibitors of atp synthesis
|
KR20070094754A
(ko)
|
2004-12-01 |
2007-09-21 |
데브젠 엔브이 |
이온 채널, 특히 Kv 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
EP1938691A3
(en)
|
2004-12-17 |
2009-07-22 |
Devgen NV |
Nematicidal compositions
|
RU2416616C2
(ru)
*
|
2005-01-19 |
2011-04-20 |
Райджел Фармасьютикалз, Инк. |
Пролекарства соединений 2,4-пиримидиндиамина и их применения
|
EP1855672A4
(en)
*
|
2005-03-11 |
2011-11-30 |
Glaxosmithkline Llc |
HIV PROTEASE INHIBITORS
|
AR053845A1
(es)
|
2005-04-15 |
2007-05-23 |
Tibotec Pharm Ltd |
5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
|
CA2606025A1
(en)
|
2005-04-27 |
2006-11-02 |
Ambrilia Biopharma Inc. |
Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
|
EP1940856B1
(en)
|
2005-10-21 |
2014-10-08 |
Universiteit Antwerpen |
Novel urokinase inhibitors
|
AR057182A1
(es)
|
2005-11-28 |
2007-11-21 |
Tibotec Pharm Ltd |
Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
AR058238A1
(es)
|
2005-11-28 |
2008-01-23 |
Tibotec Pharm Ltd |
Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
DK1954718T3
(en)
|
2005-11-30 |
2014-12-15 |
Abbvie Inc |
Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
|
AU2006319716B2
(en)
*
|
2005-11-30 |
2012-02-02 |
Taimed Biologics, Inc. |
Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
|
EP1976877B2
(en)
|
2005-11-30 |
2016-10-05 |
AbbVie Inc. |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
AU2006330277B2
(en)
*
|
2005-12-27 |
2011-10-06 |
Otsuka Pharmaceutical Co., Ltd. |
Water-soluble benzoazepine compound and its pharmaceutical composition
|
BRPI0714211B8
(pt)
|
2006-07-13 |
2021-05-25 |
Janssen Pharmaceutica Nv |
derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende
|
WO2008028688A2
(en)
|
2006-09-08 |
2008-03-13 |
Bayer Schering Pharma Aktiengesellschaft |
Compounds and methods for 18f labeled agents
|
CA2664118A1
(en)
|
2006-09-21 |
2008-07-03 |
Ambrilia Biopharma Inc. |
Protease inhibitors
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
EP2522367B1
(en)
*
|
2007-03-12 |
2016-01-20 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
JP5536647B2
(ja)
|
2007-07-27 |
2014-07-02 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ピロロピリミジン
|
EP2053033A1
(en)
|
2007-10-26 |
2009-04-29 |
Bayer Schering Pharma AG |
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
|
EP2100900A1
(en)
|
2008-03-07 |
2009-09-16 |
Universitätsspital Basel |
Bombesin analog peptide antagonist conjugates
|
DK2283024T3
(da)
|
2008-03-10 |
2013-08-05 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
|
US9095620B2
(en)
*
|
2008-03-12 |
2015-08-04 |
Nektar Therapeutics |
Reagents
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
WO2010005986A1
(en)
|
2008-07-08 |
2010-01-14 |
Gilead Sciences, Inc. |
Salts of hiv inhibitor compounds
|
KR101687841B1
(ko)
|
2008-12-09 |
2016-12-19 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
US20120135965A1
(en)
*
|
2009-05-20 |
2012-05-31 |
Ranbaxy Laboratories Limited |
Amorphous fosamprenavir calcium
|
JP2012530069A
(ja)
|
2009-06-12 |
2012-11-29 |
ネクター セラピューティックス |
プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
|
US9085592B2
(en)
|
2009-09-16 |
2015-07-21 |
Ranbaxy Laboratories Limited |
Process for the preparation of fosamprenavir calcium
|
WO2011061590A1
(en)
|
2009-11-17 |
2011-05-26 |
Hetero Research Foundation |
Novel carboxamide derivatives as hiv inhibitors
|
EP2501431B1
(en)
|
2009-11-19 |
2020-01-08 |
Wellinq Medical B.V. |
Narrow profile composition-releasing expandable medical balloon catheter
|
WO2011085130A1
(en)
|
2010-01-07 |
2011-07-14 |
Pliva Hrvatska D.O.O. |
Solid state forms of fosamprenavir calcium salt and process for preparation thereof
|
DK3494972T3
(da)
|
2010-01-27 |
2024-01-29 |
Viiv Healthcare Co |
Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20110224443A1
(en)
*
|
2010-03-15 |
2011-09-15 |
Venkata Naga Brahmeshwara Rao Mandava |
Preparation of fosamprenavir calcium
|
WO2011114212A1
(en)
|
2010-03-19 |
2011-09-22 |
Lupin Limited |
Ammonium, calcium and tris salts of fosamprenavir
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2011141515A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Pharma Aktiengesellschaft |
Diagnostic agents for amyloid beta imaging
|
US20130211108A1
(en)
|
2010-06-18 |
2013-08-15 |
Mylan Laboratories Ltd |
Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
EP2614055A2
(en)
*
|
2010-09-10 |
2013-07-17 |
Lupin Limited |
Process for preparation of substantially pure fosamprenavir calcium and its intermediates
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
WO2012085625A1
(en)
|
2010-12-21 |
2012-06-28 |
Lupin Limited |
Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
|
US8993786B2
(en)
*
|
2011-02-10 |
2015-03-31 |
Mylan Laboratories Ltd. |
Crystalline fosamprenavir calcium and process for the preparation thereof
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9309213B2
(en)
|
2011-07-11 |
2016-04-12 |
Purdue Research Foundation |
C-3 substituted bicyclooctane based HIV protease inhibitors
|
WO2013011485A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of sulfonamides useful as retroviral protease inhibitors
|
WO2013105118A1
(en)
|
2012-01-10 |
2013-07-18 |
Council Of Scientific & Industrial Research |
A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2700396A3
(en)
|
2012-06-20 |
2015-04-29 |
Sylphar Nv |
Strip for the delivery of oral care compositions
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
EP2912047B1
(en)
|
2012-10-29 |
2016-08-24 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
ES2657608T3
(es)
|
2012-12-05 |
2018-03-06 |
Alnylam Pharmaceuticals, Inc. |
Composiciones de arni de pcsk9 y métodos de uso de las mismas
|
RS56663B1
(sr)
|
2013-03-14 |
2018-03-30 |
Alnylam Pharmaceuticals Inc |
Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
|
SG10201804472YA
(en)
|
2013-05-22 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
EP3960860A3
(en)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
CN112852809A
(zh)
|
2014-05-22 |
2021-05-28 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
EP3180003B1
(en)
|
2014-07-01 |
2022-01-12 |
The Regents of the University of California |
Pkc-epsilon inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
NZ728072A
(en)
|
2014-07-11 |
2018-06-29 |
Gilead Sciences Inc |
Modulators of toll-like receptors for the treatment of hiv
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
US9738664B2
(en)
|
2014-10-29 |
2017-08-22 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of HIV protease
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
EP3256587A2
(en)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
WO2016168286A1
(en)
|
2015-04-13 |
2016-10-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
CN108025187A
(zh)
|
2015-04-28 |
2018-05-11 |
新南创新私人有限公司 |
靶向nad+以治疗化学疗法和放射疗法引发的认知损害、神经病变和不活动
|
TWI727948B
(zh)
|
2015-05-06 |
2021-05-21 |
美商阿尼拉製藥公司 |
第十二因子(哈格曼因子)(F12)、激肽釋放素B、血漿(夫列契因子)1(KLKB1)及激肽原1(KNG1)iRNA組成物及其使用方法
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
SG11201804729RA
(en)
|
2015-12-07 |
2018-07-30 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
DK3621963T3
(da)
|
2017-05-11 |
2024-04-15 |
Remynd N V |
Forbindelser til behandling af epilepsi, neurodegenerative lidelser og andre CNS-lidelser
|
US11564921B2
(en)
|
2017-07-21 |
2023-01-31 |
Viiv Healthcare Company |
Regimens for treating HIV infections and AIDS
|
WO2019027920A1
(en)
|
2017-08-01 |
2019-02-07 |
Gilead Sciences, Inc. |
CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
AR114551A1
(es)
|
2018-08-13 |
2020-09-16 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
JP2023514443A
(ja)
|
2020-02-24 |
2023-04-05 |
カトリーケ、ユニベルシテート、ルーベン |
ピロロピリジンおよびイミダゾピリジン抗ウイルス化合物
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
WO2022136486A1
(en)
|
2020-12-22 |
2022-06-30 |
Luxembourg Institute Of Health (Lih) |
Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
|
EP4301369A1
(en)
|
2021-03-04 |
2024-01-10 |
Universiteit Antwerpen |
Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
|
EP4347541A2
(en)
|
2021-05-31 |
2024-04-10 |
Telix Pharmaceuticals (Innovations) Pty Ltd |
Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024062043A1
(en)
|
2022-09-21 |
2024-03-28 |
Universiteit Antwerpen |
Substituted phenothiazines as ferroptosis inhibitors
|